Immune Tolerance Network (UM1 Clinical Trial Required)
National Institutes of Health
Summary
The purpose of this notice of funding opportunity (NOFO) is to support applications to continue the Immune Tolerance Network (ITN). The primary objective of the Network is to develop tolerogenic therapies for immune-mediated disorders. The three main clinical areas of work are: 1) Allergic diseases and asthma; 2) Autoimmune diseases; and 3) Immune-mediated consequences of transplantation. The core functions of the ITN include designing, conducting, and sharing the results of clinical trials and performing integrated mechanistic studies.
Related documents
Eligibility
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions). | applicant types: Independent school districts; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Special district governments; County governments; Public and State controlled institutions of higher education; Others (see text field entitled "Additional Information on Eligibility" for clarification); For profit organizations other than small businesses; Small businesses; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Native American tribal organizations (other than Federally recognized tribal governments); Private institutions of higher education; Public housing authorities/Indian housing authorities; City or township governments; Native American tribal governments (Federally recognized); State governments